While Eli Lilly says its blockbuster weight-loss drugs Zepbound and Mounjaro are now available, a pharmacy compounding group tells Inside Health Policy the term “available” is misleading as its not certain whether the company will be able to fulfill the demand of patients, and compounding is continuing. According to FDA’s most recent drug shortage list , both medications are now available, but tirzepatide injection is still listed as “currently in shortage.” Scott Brunner, chief executive officer at Alliance for...